Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Modulator and Leukemia Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ASXL2 drug discovery. Key functional domains: HTH HARE-type and DEUBAD (UniProt Q76L83). Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ASXL2 Recombinant Protein (HTH HARE-type / DEUBAD Domains) – High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for SPR and PROTAC assays. | View ASXL2 Products |
| Gene Delivery | ASXL2 Promise-ORF / Lentivirus – Full-length ORF for stable cell lines and intracellular expression. | View ASXL2 Products |
| Benchmark Ab | Anti-ASXL2 (Recombinant rabbit monoclonal) – Positive control for western blot and target engagement assays. | View ASXL2 Products |
| Validator | ASXL2 siRNA Set – For knockdown verification and specificity checks. | View ASXL2 Products |
| Related Target A | BAP1 – Core functional binding partner (PR-DUB complex); critical for protein-protein interaction (PPI) disruption assays. | View BAP1 Products |
| Related Target B | ASXL1 – Homolog target for selectivity and off-target counter-screening. | View ASXL1 Products |
| Related Target C | EZH2 – PRC2 component; orthogonal pathway target for combination therapy screening. | View EZH2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter-screening (ASXL1 vs ASXL3) | Homolog panel proteins strictly verified by mass spectrometry and sequence alignment. |
| PPI Disruption Validation (BAP1-ASXL2) | High purity (>95%) ASXL2 domains (HTH HARE-type, DEUBAD) optimized for AlphaScreen and FRET binding assays. |
| Nuclear Protein Solubility & Folding | HEK293 expressed with optimized solubility tags; >95% purity confirmed by SDS-PAGE and SEC. |
| Mutant Functional Analysis (Cancer Variants) | Cancer hotspot mutants (e.g., R693*, E1159fs) available as sequence-verified constructs. |
| Domain Mapping for Epitope Identification | Truncated constructs (PHD finger, ASXN, ASXM) for precise binding site determination. |
| Lack of Cellular Functional Controls | Validated siRNA included for specificity checks and target dependence confirmation. |
| Evaluating Drug-Resistant/Cancer Mutations | Custom synthetic and pre-made mutant recombinant proteins (Theoretical MW verified). |
Live ASXL2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ASXL2 therapeutics is intensifying, with major players shifting focus from traditional generic epigenetic inhibitors to targeted small molecules and PROTAC degraders. As an essential component of the PR-DUB (Polycomb repressive deubiquitinase) complex, ASXL2 has emerged as a crucial dependency in t(8;21) Acute Myeloid Leukemia (AML) and various solid tumors. ASXL2 alterations are increasingly recognized in breast and colorectal cancers. The therapeutic strategy focuses on disrupting the PR-DUB complex formation between ASXL2 and BAP1, or modulating the HTH HARE-type and DEUBAD domain-mediated interactions. Key mutations include dbSNP:rs13385963, rs17854251, and rs12991178. As first-generation epigenetic therapies reach the clinic, the next wave of R&D is targeting the specific disruption of the BAP1-ASXL2 protein-protein interaction and the utilization of targeted protein degradation to achieve sustained therapeutic responses.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Preclinical biotech spin-outs; Pharma pipelines (undisclosed) | Acute Myeloid Leukemia (AML); Hematologic Malignancies | Ternary Complex Formation (Need high-purity recombinant proteins); Cellular Ubiquitination Assay (Need Lentivirus for stable ASXL2 expression) |
| Small Molecule (PPI Inhibitor) | Epigenetic-focused pharmas; Academic programs | Breast Cancer, Colorectal Cancer; Myeloid Malignancies | Selectivity Assay (Need ASXL1/ASXL2/ASXL3 Homolog panels); ASXL2-BAP1 Binding Assay (Need high-purity full-length & domain proteins) |
| Domain-Specific Inhibitor (PHD Finger) | Structural biology consortia | Epigenetic Dysregulation Syndromes | PHD Domain Constructs (Need precise truncation mutants for crystallography) |
Key Functional Domains and Mutations
ASXL2 contains two identified functional domains: the HTH HARE-type domain and the DEUBAD domain (UniProt Q76L83). Critical mutations include dbSNP:rs13385963, rs17854251, and rs12991178, which are relevant for cancer research and drug resistance studies.